SANTORO, MASSIMO
SANTORO, MASSIMO
DIPARTIMENTO DI MEDICINA MOLECOLARE E BIOTECNOLOGIE MEDICHE
Molecular mechanisms of RET activation in human cancer
2002 Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo
Ret-mediated mitogenesis requires Src kinase activity.
1999 Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo
Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels.
2003 Wang, J; Knauf, Ja; Basu, S; Puxeddu, E; Kuroda, H; Santoro, Massimo; Fusco, Alfredo; Fagin, Ja
Tyrosine 1062 of RET-MEN2A mediates activation of Akt(PKB) and MAPK pathways leading to PC12 cell survival.
2000 DE VITA, G; Melillo, ROSA MARINA; Carlomagno, C; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, Massimo
Editorial Board Member
2009 Santoro, Massimo
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).
2003 Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
2003 Castellone, Md; Cirafici, Am; DE VITA, G; DE FALCO, V; Malorni, L; Tallini, G; Fagin, Ja; Fusco, Alfredo; Melillo, ROSA MARINA; Santoro, Massimo
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase
2002 Salvatore, Giuliana; Nagata, S.; Billaud, M.; Santoro, Massimo; Vecchio, Giancarlo; Pastan, I.
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.
2002 Pelicci, G; Troglio, F; Bodini, A; Melillo, ROSA MARINA; Pettirossi, V; Coda, L; DE GIUSEPPE, A; Santoro, Massimo; Pelicci, Pg
The RET receptor: function in development and dysfunction in congenital malformation.
2001 Manie, S; Santoro, Massimo; Fusco, Alfredo; Billaud, M.
RET activation and clinicopathologic features in poorly differentiated thyroid tumors.
2002 Santoro, Massimo; Papotti, M; Chiappetta, G; GARCIA ROSTAN, G; Volante, M; Johnson, C; Camp, Rl; Pentimalli, F; Monaco, C; Herrero, A; Carcangiu, Ml; Fusco, Alfredo
Thyroid cell transformation:the role of ras oncogene in vivo e in vitro
1985 Colletta, G.; Fusco, Alfredo; Cirafici, A.; Ciliberto, F.; Santoro, Massimo; Vecchio, Giancarlo
Monitoraggio terapeutico dei farmaci antineoplstici farmacocinetica clinica.
2009 Santoro, Massimo
Tumore delle vie respiratorie: dalla caratterizzazione molecolare allo sviluppo di terapie "paient tailored".
2010 Santoro, Massimo
Thyroid neoplastic transformation: role of the RET oncogene.
2007 Santoro, Massimo
Monitoraggio terapeutico dei farmaci antineoplastici e farmacocinetica clinica.
2007 Santoro, Massimo
Genetics of differentiated thyroid cancer
2007 Santoro, Massimo
The receptor tyrosine kinase RET is a Hsp90 client protein and is degraded upon exposure to 17-AAG.
2009 Santoro, Massimo
Molecular targeting of the RET kinase in thyroid cancer treatment
2007 Santoro, Massimo
Protein kinase inhibitors for treatment of thyroid carcinoma
2008 Santoro, Massimo
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Molecular mechanisms of RET activation in human cancer | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Santoro, Massimo; Melillo, Rosa Marina; Carlomagno, F; Fusco, Alfredo; Vecchio, Giancarlo | |
| Ret-mediated mitogenesis requires Src kinase activity. | 1.1 Articolo in rivista | 1999 | Melillo, Rosa Marina; Barone, Mv; Lupoli, G; Cirafici, Am; Carlomagno, F; Visconti, R; Matoskova, B; Di Fiore, Pp; Vecchio, G; Fusco, Alfredo; Santoro, Massimo | |
| Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. | 1.1 Articolo in rivista | 2003 | Wang, J; Knauf, Ja; Basu, S; Puxeddu, E; Kuroda, H; Santoro, Massimo; Fusco, Alfredo; Fagin, Ja | |
| Tyrosine 1062 of RET-MEN2A mediates activation of Akt(PKB) and MAPK pathways leading to PC12 cell survival. | 1.1 Articolo in rivista | 2000 | DE VITA, G; Melillo, ROSA MARINA; Carlomagno, C; Visconti, R; Castellone, Md; Bellacosa, A; Billaud, M; Fusco, Alfredo; Tsichlis, Pn; Santoro, Massimo | |
| Editorial Board Member | 8.06 Partecip. Editorial Board di riviste scientifiche | 2009 | Santoro, Massimo | |
| Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | 1.1 Articolo in rivista | 2003 | Carlomagno, F; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo | |
| Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. | 1.1 Articolo in rivista | 2003 | Castellone, Md; Cirafici, Am; DE VITA, G; DE FALCO, V; Malorni, L; Tallini, G; Fagin, Ja; Fusco, Alfredo; Melillo, ROSA MARINA; Santoro, Massimo | |
| Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase | 1.1 Articolo in rivista | 2002 | Salvatore, Giuliana; Nagata, S.; Billaud, M.; Santoro, Massimo; Vecchio, Giancarlo; Pastan, I. | |
| The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. | 1.1 Articolo in rivista | 2002 | Pelicci, G; Troglio, F; Bodini, A; Melillo, ROSA MARINA; Pettirossi, V; Coda, L; DE GIUSEPPE, A; Santoro, Massimo; Pelicci, Pg | |
| The RET receptor: function in development and dysfunction in congenital malformation. | 1.1 Articolo in rivista | 2001 | Manie, S; Santoro, Massimo; Fusco, Alfredo; Billaud, M. | |
| RET activation and clinicopathologic features in poorly differentiated thyroid tumors. | 1.1 Articolo in rivista | 2002 | Santoro, Massimo; Papotti, M; Chiappetta, G; GARCIA ROSTAN, G; Volante, M; Johnson, C; Camp, Rl; Pentimalli, F; Monaco, C; Herrero, A; Carcangiu, Ml; Fusco, Alfredo | |
| Thyroid cell transformation:the role of ras oncogene in vivo e in vitro | 2.1 Contributo in volume (Capitolo o Saggio) | 1985 | Colletta, G.; Fusco, Alfredo; Cirafici, A.; Ciliberto, F.; Santoro, Massimo; Vecchio, Giancarlo | |
| Monitoraggio terapeutico dei farmaci antineoplstici farmacocinetica clinica. | 8.03 Conv. e contr. di ricerca di Enti Pubblici/Privati | 2009 | Santoro, Massimo | |
| Tumore delle vie respiratorie: dalla caratterizzazione molecolare allo sviluppo di terapie "paient tailored". | 8.07 Progetti di Ricerca Finanziati | 2010 | Santoro, Massimo | |
| Thyroid neoplastic transformation: role of the RET oncogene. | 8.03 Conv. e contr. di ricerca di Enti Pubblici/Privati | 2007 | Santoro, Massimo | |
| Monitoraggio terapeutico dei farmaci antineoplastici e farmacocinetica clinica. | 8.03 Conv. e contr. di ricerca di Enti Pubblici/Privati | 2007 | Santoro, Massimo | |
| Genetics of differentiated thyroid cancer | 8.02 Comunicazioni a Convegni o Seminari | 2007 | Santoro, Massimo | |
| The receptor tyrosine kinase RET is a Hsp90 client protein and is degraded upon exposure to 17-AAG. | 8.10 Tesi di Dottorato | 2009 | Santoro, Massimo | |
| Molecular targeting of the RET kinase in thyroid cancer treatment | 8.02 Comunicazioni a Convegni o Seminari | 2007 | Santoro, Massimo | |
| Protein kinase inhibitors for treatment of thyroid carcinoma | 8.02 Comunicazioni a Convegni o Seminari | 2008 | Santoro, Massimo |